Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 447 of 6351
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThe main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because …
Phase 3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug cocktail aims to tackle lung cancer brain metastases
Disease control Not yet recruitingThis is a prospective, open-label, multi-center, single-arm clinical trial
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Phase 2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Immunotherapy plus chemo aims to extend lives in tough lung cancer
Disease control Not yet recruitingThis is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung
Phase 2 • Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New gene therapy hopes to fix fatal brain diseases
Disease control Not yet recruitingThe project aims to optimize and validate this new therapeutic strategy using cells from GM2 patients to evaluate the cross-correction of neurons in vitro by the culture medium of genetically modified myeloid cell lines. The ultimate goal is to demonstrate the potential of CHS-TG…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail targets brain tumors from lung and breast cancer
Disease control CancelledBrain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of primary malignant brain tumors. Over 80% of patients …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New shot could tame inherited high cholesterol
Disease control Not yet recruitingThis Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for advanced penile cancer: drug combo targets tough cases
Disease control Not yet recruitingPenile cancer is a rare malignant tumor of the male genitourinary system, with 95% being squamous cell carcinoma. Due to social factors, delayed diagnosis is common, leading to a high rate of lymph node metastasis (17%-45% at diagnosis), which significantly impairs quality of lif…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for rare kidney cancer: targeted drug plus radiation may replace chemo
Disease control Not yet recruitingThis randomized, open-label, multicenter phase II study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU). Eli…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
PET scans could guide smarter breast cancer therapy
Disease control Not yet recruitingThis study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer. Based on metabolic response after two cycles, patients receive either intenstified treatment (Arm A) or de-escalation treatment (Arm B), a…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a simple blood injection help women with uterine scarring get pregnant?
Disease control Not yet recruitingIntrauterine adhesions (IUA) caused by endometrial basal layer injury can lead to reduced menstrual flow, infertility, recurrent pregnancy loss, and poor reproductive outcomes. Hysteroscopic adhesiolysis with uterine cavity reconstruction is the standard treatment, but women with…
Sponsor: Beijing Obstetrics and Gynecology Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktail shows promise in shrinking lung tumors before surgery
Disease control Not yet recruitingBackground: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation. Iparomlimab and tuvonralimab (QL1706) is a novel bifunctional antibody combination targeting PD-1 and CTLA…
Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Liver cancer hope: triple therapy shows promise in early trial
Disease control Not yet recruitingThis is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion chemotherapy (TACE-HAIC) as first-line treatment f…
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to cut opioid use after heart and Weight-Loss surgery
Symptom relief Recruiting nowThis is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy…
Phase 3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New immune cell therapy takes on tough pancreatic cancer
Disease control Not yet recruitingChemotherapy is the first-line treatment for advanced-stage pancreatic cancer patients. However, drug resistance always occurs within 6 months. For these patients, no effective treatment is available. Chimeric antigen receptor macrophage targeting C-MET( CAR-M-C-MET) is a novel c…
Phase 1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for rare leukemia: drug cocktail aims for remission
Disease control Not yet recruitingThis is a prospective, open-label, single-arm, two-cohort Phase 2 clinical study designed to evaluate the efficacy and safety of Bcl-2 Inhibitor combined with azacitidine (with blinatumomab added in B/myeloid subtype) in patients with newly diagnosed mixed phenotype acute leukemi…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Arm cuff therapy may shield heart and brain after stroke
Disease control Not yet recruitingIntroduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovas…
Phase 3 • Sponsor: Capital Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Nose cells and exercise: a new hope for spinal cord repair?
Disease control Not yet recruitingThis is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined cell transplantation and intensive rehabilitation intervention to treat spinal cord injury. The trial aims to examine whether transplantation of olfactory cell…
Phase 1 • Sponsor: Dr Brent McMonagle • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Migraine drug may boost CAR-T therapy in tough lymphoma
Disease control Not yet recruitingThis study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cel…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Gene test could tailor chemo for tough pancreatic cancers
Knowledge-focused Not yet recruitingPancreatic cancer exhibits significant heterogeneity, which poses a major challenge in selecting the best treatment for patients from the very beginning of care. Modern oncology recognizes the use of companion biomarkers to guide targeted therapy or immune checkpoint inhibitors. …
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC